{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:29:09Z","timestamp":1781288949445,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In lung cancer management, differential diagnosis between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IMP) is a critical point that is of direct therapeutic and clinical importance. However, this process often suffers from absence of a gold standard, resulting in equivocal cases. Herein, we present a series of three cases, in which genomic alteration patterns revealed by next-generation sequencing (NGS) facilitated the differential diagnosis between MPLC and IMP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Case 1 was a 57-year-old female with two separate lesions in the upper lobe and the lower lobe of left lung, which were both histopathologically determined as T2aN0M0 adenocarcinomas. NGS identified an <jats:italic>EGFR<\/jats:italic> L858R in one lesion and an <jats:italic>EGFR<\/jats:italic> 20 exon insertion in the other one, suggestive of double primary malignancies. The patient underwent wedge resections and received an adjuvant treatment of icotinib and chemotherapy. She had a disease-free survival (DFS) of 19\u2009months and counting. Case 2 was a 55-year-old female with multiple small lesions in both lungs. Histopathological examinations of resected lesions from right upper lobe revealed three subtypes: atypical adenomatous hyperplasia of alveolar epithelium, adenocarcinomas in situ and minimally invasive adenocarcinoma. NGS identified two different <jats:italic>BRAF<\/jats:italic> driver mutations G466E and V600_K601delinsE in two lesions of adenocarcinoma in situ, and a <jats:italic>BRAF<\/jats:italic> K601E in a lesion of minimally invasive adenocarcinoma. Case 3, a 68-year-old male, had the right upper lobe lesion histophathologically classified as a stage T3NxM0 mixed adenoneuroendocrine carcinoma and the left upper lobe lesion as a stage T1aN0M0 adenocarcinoma. NGS performed with different loci of surgical tissues revealed a rare sensitizing <jats:italic>EGFR<\/jats:italic> mutation G719A shared by the right upper lobe lesion and lymph node, and two <jats:italic>EGFR<\/jats:italic> mutations L861Q and G719S in left upper lobe lesion. The patient received icotinib treatment postoperatively and achieved a stable disease with a progression-free survival of 5\u2009months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our cases provide evidence for utility of NGS in facilitating diagnosis and treatment decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-021-01083-6","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T16:02:52Z","timestamp":1615478572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series"],"prefix":"10.1186","volume":"16","author":[{"given":"Changjiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-0088","authenticated-orcid":false,"given":"Yang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"4","key":"1083_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0022-5223(19)40289-4","volume":"70","author":"N Martini","year":"1975","unstructured":"Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606\u201312. https:\/\/doi.org\/10.1016\/S0022-5223(19)40289-4.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"1083_CR2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/JTO.0b013e3181e15d8c","volume":"5","author":"H Asamura","year":"2010","unstructured":"Asamura H. Multiple primary cancers or multiple metastases, that is the question. J Thorac Oncol. 2010;5(7):930\u20131. https:\/\/doi.org\/10.1097\/JTO.0b013e3181e15d8c.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 4","key":"1083_CR3","doi-asserted-by":"publisher","first-page":"S523","DOI":"10.21037\/jtd.2019.01.56","volume":"11","author":"C Chen","year":"2019","unstructured":"Chen C, Huang X, Peng M, Liu W, Yu F, Wang X. Multiple primary lung cancer: a rising challenge. J Thorac Dis. 2019;11(Suppl 4):S523\u2013S36. https:\/\/doi.org\/10.21037\/jtd.2019.01.56.","journal-title":"J Thorac Dis"},{"issue":"8","key":"1083_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/jnci\/djp059","volume":"101","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF, Minna JD. Multifocal lung cancers--clonality vs field cancerization and does it matter? J Natl Cancer Inst. 2009;101(8):541\u20133. https:\/\/doi.org\/10.1093\/jnci\/djp059.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1083_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.21037\/tlcr.2017.06.11","volume":"6","author":"F Schneider","year":"2017","unstructured":"Schneider F, Dacic S. Histopathologic and molecular approach to staging of multiple lung nodules. Transl Lung Cancer Res. 2017;6(5):540\u20139. https:\/\/doi.org\/10.21037\/tlcr.2017.06.11.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"1083_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-015-0207-9","volume":"34","author":"J Sherwood","year":"2015","unstructured":"Sherwood J, Dearden S, Ratcliffe M, Walker J. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res. 2015;34(1):92. https:\/\/doi.org\/10.1186\/s13046-015-0207-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"1083_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jnci\/djp054","volume":"101","author":"X Wang","year":"2009","unstructured":"Wang X, Wang M, MacLennan GT, Abdul-Karim FW, Eble JN, Jones TD, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101(8):560\u201370. https:\/\/doi.org\/10.1093\/jnci\/djp054.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1083_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1309\/AJCPNBWF55VGKOIW","volume":"143","author":"RJ Homer","year":"2015","unstructured":"Homer RJ. Pathologists\u2019 staging of multiple foci of lung cancer: poor concordance in absence of dramatic histologic or molecular differences. Am J Clin Pathol. 2015;143(5):701\u20136. https:\/\/doi.org\/10.1309\/AJCPNBWF55VGKOIW.","journal-title":"Am J Clin Pathol"},{"issue":"22","key":"1083_CR9","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1200\/JCO.2010.33.3906","volume":"29","author":"Y Yatabe","year":"2011","unstructured":"Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29(22):2972\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.33.3906.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1083_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jtho.2019.01.017","volume":"14","author":"A Mansuet-Lupo","year":"2019","unstructured":"Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, le Hay C, Cremer I, R\u00e9gnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H. Proposal for a combined Histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol. 2019;14(5):844\u201356. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.017.","journal-title":"J Thorac Oncol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-021-01083-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T16:03:27Z","timestamp":1615478607000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-021-01083-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1186\/s13000-021-01083-6","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study was a case series without Protected Health Information, ethics approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from the patients or family of the patient for publication of this Case series and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"XZ, LS and YS report that they are employees of Burning Rock Biotech. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}